BR9916069A - Sistema de expressão para fator viii - Google Patents

Sistema de expressão para fator viii

Info

Publication number
BR9916069A
BR9916069A BR9916069-2A BR9916069A BR9916069A BR 9916069 A BR9916069 A BR 9916069A BR 9916069 A BR9916069 A BR 9916069A BR 9916069 A BR9916069 A BR 9916069A
Authority
BR
Brazil
Prior art keywords
factor viii
protein
procoagulant activity
cells
expression system
Prior art date
Application number
BR9916069-2A
Other languages
English (en)
Other versions
BRPI9916069B8 (pt
BRPI9916069B1 (pt
Inventor
Myung-Sam Cho
Sham Yuen Chan
William Kelsey
Helena Yee
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR9916069A publication Critical patent/BR9916069A/pt
Publication of BRPI9916069B1 publication Critical patent/BRPI9916069B1/pt
Publication of BRPI9916069B8 publication Critical patent/BRPI9916069B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Patente de Invenção: <B>"SISTEMA DE EXPRESSãO PARA FATOR VIII"<D>. Esta invenção descreve um processo de produção isento de proteínas para proteínas tendo atividade pró-coagulante de fator VIII. Geralmente, o processo inclui a derivação de clones de células humanas estáveis com alta produtividade para fator VIII deletado com domínio B, e (2) a adaptação de células para cultivo em um meio isento de proteínas derivadas de plasma. Mais especificamente, o processo inclui transfectar células humanas com um vetor, como na figura, compreendendo um marcador selecionável e uma seq³ência codificando a proteína tendo atividade pró-coagulante de fator VIII, selecionar células com um agente de seleção e isolar clones expressando altos níveis da proteína tendo atividade pró-coagulante de fator VIII.
BRPI9916069A 1998-12-10 1999-12-08 processo para produção e isolamento de proteína com atividade de fator viii, linhagem de célula humana híbrida com atividade de fator viii e linhagem de celula híbrida BRPI9916069B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/209,916 US6358703B1 (en) 1998-12-10 1998-12-10 Expression system for factor VIII
PCT/US1999/029169 WO2000034505A1 (en) 1998-12-10 1999-12-08 Expression system for factor viii

Publications (3)

Publication Number Publication Date
BR9916069A true BR9916069A (pt) 2001-09-04
BRPI9916069B1 BRPI9916069B1 (pt) 2016-08-02
BRPI9916069B8 BRPI9916069B8 (pt) 2021-05-25

Family

ID=22780858

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9916069A BRPI9916069B8 (pt) 1998-12-10 1999-12-08 processo para produção e isolamento de proteína com atividade de fator viii, linhagem de célula humana híbrida com atividade de fator viii e linhagem de celula híbrida

Country Status (26)

Country Link
US (10) US6358703B1 (pt)
EP (1) EP1137797B1 (pt)
JP (1) JP4240818B2 (pt)
KR (1) KR100616028B1 (pt)
AT (1) ATE412765T1 (pt)
AU (1) AU761801B2 (pt)
BG (1) BG65431B1 (pt)
BR (1) BRPI9916069B8 (pt)
CA (1) CA2354845C (pt)
CZ (1) CZ302330B6 (pt)
DE (1) DE69939839D1 (pt)
DK (1) DK1137797T3 (pt)
ES (1) ES2315026T3 (pt)
HU (1) HU228489B1 (pt)
IL (2) IL143353A0 (pt)
NO (1) NO329544B1 (pt)
NZ (1) NZ512234A (pt)
PL (1) PL200676B1 (pt)
PT (1) PT1137797E (pt)
RO (1) RO121604B1 (pt)
RU (1) RU2249041C2 (pt)
SI (1) SI20644B (pt)
SK (1) SK286945B6 (pt)
TR (1) TR200101592T2 (pt)
UA (1) UA77383C2 (pt)
WO (1) WO2000034505A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
US7572619B2 (en) * 2000-03-22 2009-08-11 Octagene Gmbh Recombinant blood clotting factors
US7205278B2 (en) * 2001-06-14 2007-04-17 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
CN102139114A (zh) * 2003-02-26 2011-08-03 尼克塔治疗公司 聚合物-因子viii部分缀合物
US7498024B2 (en) * 2003-06-03 2009-03-03 Cell Genesys, Inc. Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
EP1812557A4 (en) * 2004-10-29 2009-11-04 Centocor Ortho Biotech Inc COMPOSITIONS OF CHEMICALLY DEFINED MEDIA
PT2371856T (pt) * 2004-11-12 2022-08-12 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
PE20080556A1 (es) 2005-12-20 2008-06-13 Bristol Myers Squibb Co Composicion que comprende una poblacion aislada de moleculas ctla4-ig a partir de un medio de cultivo liquido y metodos para su obtencion
PT2235197T (pt) * 2007-12-27 2017-10-11 Baxalta Inc Processos para cultura de células
KR101005967B1 (ko) 2008-04-12 2011-01-05 (주)셀트리온 우수한 재조합 단백질을 생산하기 위한 인간 숙주 세포
US20110112022A1 (en) * 2008-06-25 2011-05-12 Bayer Healthcare Llc Factor VIII Muteins with Reduced Immonugenicity
MX2011001624A (es) 2008-08-21 2011-03-28 Octapharma Ag Factor viii y ix humano producido en forma recombinante.
SI2337580T1 (sl) * 2008-09-03 2012-06-29 Octapharma Ag Stabilizirani sestavki za rekombinanto proizveden faktor VIII
CN102348715B (zh) 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
US20120142593A1 (en) * 2009-03-24 2012-06-07 Bayer Healthcare Llc Factor VIII Variants and Methods of Use
AU2010290077C1 (en) 2009-08-24 2015-12-03 Bioverativ Therapeutics Inc. Coagulation factor IX compositions and methods of making and using same
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
RU2600886C2 (ru) 2011-05-13 2016-10-27 Октафарма Аг Способ повышения продуктивности эукариотических клеток в продуцировании рекомбинантного fviii
WO2013106787A1 (en) 2012-01-12 2013-07-18 Biogen Idec Ma Inc. Chimeric factor viii polypeptides and uses thereof
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
RS63870B1 (sr) * 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
CN117106095A (zh) 2014-01-10 2023-11-24 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
AU2017250570B2 (en) 2016-04-15 2024-07-25 Takeda Pharmaceutical Company Limited Method and apparatus for providing a pharmacokinetic drug dosing regiment
US11628205B2 (en) 2016-07-22 2023-04-18 Nektar Therapeutics Conjugates of a factor VIII moiety having an oxime-containing linkage
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
WO2019055717A1 (en) * 2017-09-13 2019-03-21 Evolve Biosystems, Inc. OLIGOSACCHARIDE COMPOSITIONS AND THEIR USE DURING THE TRANSIENT PHASES OF INTESTINAL MICROBIOMA OF A MAMMALIAN
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
JP2021523878A (ja) 2018-05-18 2021-09-09 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
CA3115535A1 (en) * 2018-10-23 2020-04-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR890002004B1 (ko) * 1984-01-11 1989-06-07 가부시끼 가이샤 도오시바 지폐류 판별장치
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
CA1341174C (en) * 1985-04-12 2001-01-30 John J. Toole Jr. Procoagulant proteins derived from factor viii: c
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
EP0254076B1 (en) * 1986-07-11 1991-05-08 Miles Inc. Improved recombinant protein production
IE872455L (en) 1986-09-12 1988-03-12 Lanstrase Ltd Improved recombinant expression
IE69026B1 (en) * 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
ES2226029T3 (es) * 1993-06-10 2005-03-16 Bayer Corporation Vector y linea celular de mamifero con productividad mejorada.
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
DE19517194A1 (de) * 1995-05-11 1996-11-14 Giesecke & Devrient Gmbh Vorrichtung und Verfahren zur Prüfung von Blattgut, wie z.B. Banknoten oder Wertpapiere
MX9504215A (es) 1995-10-05 1997-04-30 Inst Politecnico Nacional Procedimiento mejorado para la purificacion de oligopeptidos con pesos moleculares de 1000 a 10,000 daltones, a partir de estractos leucocitos y su presentacion farmaceutica.
US5922959A (en) * 1996-10-15 1999-07-13 Currency Systems International Methods of measuring currency limpness
US5923413A (en) * 1996-11-15 1999-07-13 Interbold Universal bank note denominator and validator
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
WO1999029848A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6040584A (en) * 1998-05-22 2000-03-21 Mti Corporation Method and for system for detecting damaged bills
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6136599A (en) * 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII

Also Published As

Publication number Publication date
BRPI9916069B8 (pt) 2021-05-25
US20030077752A1 (en) 2003-04-24
KR100616028B1 (ko) 2006-08-28
PL200676B1 (pl) 2009-01-30
NO20012718D0 (no) 2001-06-01
SI20644A (sl) 2002-02-28
IL143353A0 (en) 2002-04-21
ATE412765T1 (de) 2008-11-15
UA77383C2 (uk) 2006-12-15
BG65431B1 (bg) 2008-07-31
EP1137797B1 (en) 2008-10-29
BG105567A (en) 2002-03-29
US20110144025A1 (en) 2011-06-16
BRPI9916069B1 (pt) 2016-08-02
ES2315026T3 (es) 2009-03-16
CA2354845A1 (en) 2000-06-15
US20020102730A1 (en) 2002-08-01
US7459525B2 (en) 2008-12-02
HUP0200558A2 (en) 2002-06-28
TR200101592T2 (tr) 2001-11-21
CZ20012024A3 (cs) 2001-10-17
PT1137797E (pt) 2008-12-26
US20160115219A1 (en) 2016-04-28
CA2354845C (en) 2008-08-12
US20170267745A1 (en) 2017-09-21
RO121604B1 (ro) 2007-12-28
JP4240818B2 (ja) 2009-03-18
US20130267468A1 (en) 2013-10-10
RU2249041C2 (ru) 2005-03-27
NO20012718L (no) 2001-06-01
HUP0200558A3 (en) 2004-11-29
HU228489B1 (en) 2013-03-28
CZ302330B6 (cs) 2011-03-16
AU761801B2 (en) 2003-06-12
AU2170100A (en) 2000-06-26
US20130143818A1 (en) 2013-06-06
NO329544B1 (no) 2010-11-08
DE69939839D1 (de) 2008-12-11
SI20644B (sl) 2009-04-30
US6358703B1 (en) 2002-03-19
US9249209B2 (en) 2016-02-02
WO2000034505A1 (en) 2000-06-15
JP2002531137A (ja) 2002-09-24
PL349284A1 (en) 2002-07-15
US20020115152A1 (en) 2002-08-22
US9650431B2 (en) 2017-05-16
IL143353A (en) 2010-12-30
EP1137797A4 (en) 2005-06-22
SK286945B6 (sk) 2009-08-06
KR20020013481A (ko) 2002-02-20
US8207117B2 (en) 2012-06-26
NZ512234A (en) 2002-12-20
SK7922001A3 (en) 2002-01-07
US20090036358A1 (en) 2009-02-05
DK1137797T3 (da) 2009-02-23
EP1137797A1 (en) 2001-10-04
US8945869B2 (en) 2015-02-03

Similar Documents

Publication Publication Date Title
BR9916069A (pt) Sistema de expressão para fator viii
Johnson et al. Nuclear accumulation of epidermal growth factor in cultured rat pituitary cells
AR056723A2 (es) Polipeptido purificado metodo para producirlo , metodo para identificarlo y/ o aislarlo composicion farmaceutica que lo comprende, secuencia de acidos nucleicos aislada que codifica dicho polipeptido, vector que contiene a dicha secuencia celula huesped transfectada por dicho vector, sonda nucleotid
BR9915604A (pt) Peptìdios inibidores de tgfbeta1
HUP9904239A2 (hu) Fehérjék nagymértékű expressziója
DE69933550D1 (de) Modifizierte adenoviren welche ein faserersatzprotein enthalten
DK0851868T3 (da) Höjniveau-ekspression af proteiner
PT733103E (pt) Criacao de elevados titulos de vectores de aav recombinantes
AU2002257420A1 (en) A system for inducible expression in eukaryotic cells
BR9406232A (pt) Novo agente para controle da atividade celular
TR199501134A2 (tr) Memeli ve viral proteinleri asiri ifade edilmesi.
EP2278021A3 (en) Expression vectors, transfection systems, and method of use thereof
DE69128893D1 (de) Genetische veränderung von endothelzellen
MXPA02002384A (es) Polipeptidos similares al factor de crecimiento de fibroblastos.
ATE288480T1 (de) Chondrogene in vitro induktion von menschlichen mensenchymalen stammzellen
AR020048A1 (es) Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero.
NO995928L (no) Alfa-1-antitrypsin-preparater samt fremgangsmåte ved fremstilling derav
NO974035L (no) En ny vekstfaktor og en genetisk sekvens som koder for denne
NO910982D0 (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
PT1025245E (pt) Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
Hitt et al. De novo and maintenance DNA methylation by a mouse plasmacytoma cell DNA methyltransferase.
DE69033756D1 (de) Gene, die für MACIF Proteine kodieren, Expressionsvektoren mit diesem Genen, und Transformantenzellen mit diesem Proteinen
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
SE9401380D0 (sv) Ny celltillväxt-relaterad peptid och användning därav
ES2170751T3 (es) Promotor aox2 mutante, vector portador del mismo, transformante, y produccion de proteina heterologa.

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/08/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 08/12/2019